Cilengitide
CAS No. 188968-51-6
Cilengitide ( EMD 121974 )
Catalog No. M12961 CAS No. 188968-51-6
Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 58 | In Stock |
|
5MG | 87 | In Stock |
|
10MG | 147 | In Stock |
|
25MG | 259 | In Stock |
|
50MG | 417 | In Stock |
|
100MG | 599 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCilengitide
-
NoteResearch use only, not for human use.
-
Brief DescriptionCilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
DescriptionCilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
-
SynonymsEMD 121974
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorαVβ3 integrin; αVβ5 integrin
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number188968-51-6
-
Formula Weight588.66
-
Molecular FormulaC27H40N8O7
-
Purity>98%(HPLC)
-
SolubilityWater: 8 mg/mL (13.59 mM); DMSO: 100 mg/mL (169.87 mM)
-
SMILESCC(C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Reardon DA, et al. Genes Y, 2011, 2(12):1159-1165.
molnova catalog
related products
-
MK-0429
MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.
-
Vedolizumab
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
-
Lifitegrast
A potent LFA-1/ICAM-1 antagonist with IC50 of 9 nM in HuT78 cells; exhibits good in vitro safety profile and low potency on CYP3A4, CYP2C9 and hERG.